CMS Draws a Harder Line on Medicare Advantage

The latest CMS rate notice is easy to misread. On paper, the agency is still increasing payments to Medicare Advantage plans in 2027. In substance, it is drawing a sharper distinction between legitimate clinical risk and revenue built on documentation tactics that have long inflated the program’s economics. That matters more than the headline payment bump, because the real policy signal is not generosity. It is discipline.

In its CY 2027 Rate Announcement, the agency projected a net average increase of 2.48 percent, or more than $13 billion in additional Medicare Advantage payments, while also continuing the 2024 risk adjustment model for another year and excluding diagnoses from unlinked chart review records from risk score calculations. That combination is deliberate. CMS is not trying to destabilize the market. It is trying to narrow the distance between payment accuracy and coding behavior.

That is a significant turn in a program that now sits at the center of Medicare rather than at its edge. A payment system of this size cannot operate indefinitely on the assumption that more documentation always reflects more illness, or that every diagnostic entry supports better care management. Once a private plan market becomes the dominant form of Medicare coverage, technical payment policy becomes health system policy.

Payment Growth With a Warning Attached

The most important part of the 2027 notice is not the increase itself. It is the condition attached to it. CMS is effectively telling plans that payment growth will continue, but the agency is less willing to tolerate forms of risk capture that are weakly connected to documented services or clinical follow through.

That stance is consistent with the broader CY 2027 MA and Part D final rule, which also revises Star Ratings, trims administrative measures that do little to distinguish plan performance, and adds a depression screening and follow up measure for future ratings. The direction is clear. CMS wants a program that can still compete on benefits and quality, but with fewer opportunities to convert administrative sophistication into federal overpayment.

The distinction matters for providers as much as for plans. A blunt rate cut would have sent one message, namely that Washington believes the program has become too expensive. This policy sends a more precise one. CMS still sees value in Medicare Advantage as a delivery model, but it is increasingly skeptical of margins generated by coding intensity rather than clinical performance, pharmacy management, or actual care coordination.

The Coding Debate Is No Longer a Side Issue

That skepticism did not emerge in a vacuum. KFF reported that 54 percent of eligible Medicare beneficiaries were enrolled in Medicare Advantage in 2025, and a subsequent 2026 update found enrollment had climbed to just over 35 million people. At that scale, risk adjustment is no longer an actuarial back office concern. It shapes federal spending, plan design, provider contracting, and the patient experience across a large share of the senior market.

The independent MedPAC has been warning for years that Medicare pays more for comparable beneficiaries in Medicare Advantage than it would under traditional Medicare. In its March 2026 report to Congress, the commission estimated that favorable selection and coding intensity together push Medicare spending for Medicare Advantage enrollees 14 percent above what the program would spend if those same beneficiaries were in fee for service Medicare, a projected difference of $76 billion in 2026.

That figure does not prove that every excess dollar is waste. Some of that payment differential helps finance supplemental benefits that beneficiaries value. But it does show why CMS can no longer treat coding intensity as a tolerable imperfection. When payment differences reach that magnitude, the issue stops being technical refinement and becomes one of stewardship.

The findings from the HHS Office of Inspector General sharpen the same point. In a 2024 report, the watchdog estimated that diagnoses reported only on health risk assessments and HRA linked chart reviews, without any other service records in the data, generated $7.5 billion in Medicare Advantage risk adjusted payments for 2023. The report also raised concerns that those diagnoses either were inaccurate or were not followed by the care that serious conditions should have triggered. That is not merely a payment integrity issue. It is a quality of care issue.

Providers Will Feel the Pressure First

Patients are unlikely to experience the 2027 changes as a visible policy event. Providers and plan operators will. The organizations most exposed are those that relied heavily on chart review based diagnosis capture that was not anchored to beneficiary encounters. Excluding unlinked chart review records from risk score calculations will not erase coding pressure across the system, but it will make some documentation strategies less valuable almost overnight.

That may produce a healthier market signal over time. Plans that have leaned too hard on diagnosis capture will need to find margin elsewhere, through better pharmacy management, tighter operations, stronger network design, or real clinical programs that reduce avoidable utilization. In theory, that should reward plans that can manage chronic disease, transitions of care, behavioral health, and medication adherence more effectively than competitors.

The near term effect, however, may be less tidy. Some plans are likely to intensify documentation scrutiny in provider contracts, press medical groups for cleaner encounter data, and rework vendor arrangements built around risk score optimization. Hospitals and physician groups may see more friction before they see relief. Administrative burden does not disappear simply because CMS targets a questionable payment source. It often shifts location first.

There is also a patient equity dimension embedded in this debate. Better payment accuracy protects taxpayers and can curb incentives for aggressive coding, but poorly calibrated restrictions can also create unintended disincentives around complex patients whose needs are real and expensive. That is one reason CMS did not pair these integrity moves with a broad payment retreat. The agency appears to be trying to strip out less defensible diagnosis sources without destabilizing benefit offerings for enrollees who depend on them.

Part D Carries the Same Message

The Part D side of the announcement received less attention, but it reinforces the same governing philosophy. CMS finalized updates to the Part D risk adjustment model to reflect more current costs, account for changes from the Inflation Reduction Act, and separately model costs for Medicare Advantage prescription drug plans and standalone prescription drug plans. That is not a side adjustment. It is another attempt to make payment better match actual program dynamics rather than inherited assumptions.

The final rule pushes in the same direction by codifying major Part D redesign changes for 2027 and beyond, including a lower annual out of pocket threshold and operational changes tied to the post IRA structure of the drug benefit. Taken together, the message across Medicare Advantage and Part D is that CMS wants a more defensible payment system, one that can still support choice and benefit richness while tolerating less imprecision.

That has broader significance for health system leaders. Drug spending, behavioral health performance, risk documentation, and supplemental benefit design are often managed in separate silos inside payer organizations and payer provider partnerships. Federal policy is increasingly forcing those functions back into the same financial conversation. Accuracy in one segment can no longer be offset indefinitely by opacity in another.

The New Margin Test

The larger meaning of the 2027 notice is that CMS is trying to change what counts as credible success in Medicare Advantage. For years, the market rewarded scale, coding sophistication, and supplemental benefit packaging, often all at once. Those capabilities will still matter. But the policy environment is becoming less hospitable to business models that depend on the assumption that more diagnoses automatically justify more federal payment.

That is a harder test for plans, but it is also a healthier one for the program. A stable future for Medicare Advantage depends on preserving what beneficiaries value while reducing the perception, and in some cases the reality, that the program pays too much for risk that is documented better than it is managed. The plans best positioned for the next phase are not necessarily those that can code the fastest. They are the ones that can show that payment accuracy, clinical follow through, and member value still point in the same direction.